Toggle Main Menu Toggle Search

Open Access padlockePrints

Reticular dysgenesis: International survey on clinical presentation, transplantation, and outcome

Lookup NU author(s): Professor Andrew GenneryORCiD, Professor Mary Slatter


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2017 by The American Society of Hematology. Reticular dysgenesis (RD) is a rare congenital disorder defined clinically by the combination of severe combined immunodeficiency (SCID), agranulocytosis, and sensorineural deafness. Mutations in the gene encoding adenylate kinase 2 were identified to cause the disorder. Hematopoietic stem cell transplantation (HSCT) is the only option to cure this otherwise fatal disease.Retrospective data on clinical presentation, genetics, and outcome of HSCT were collected from centers in Europe, Asia, and North America for a total of 32 patients born between 1982 and 2011.Age at presentationwas <4 weeks in 30 of 32 patients (94%). Grafts originated frommismatched family donors in 17 patients (55%), frommatched family donors in 6 patients (19%), and from unrelated marrow or umbilical cord blood donors in 8 patients (26%). Thirteen patients received secondary or tertiary transplants. After transplantation, 21 of 31 patients were reported alive at a mean follow-up of 7.9 years (range: 0.6-23.6 years). All patients who died beyond 6 months after HSCT had persistent or recurrent agranulocytosis due to failure of donor myeloid engraftment. In the absence of conditioning, HSCT was ineffective to overcome agranulocytosis, and inclusion of myeloablativecomponents in theconditioningregimenswasrequiredtoachievestable lymphomyeloidengraftment. Incomparisonwith other SCID entities, considerable differences were noted regarding age at presentation, onset, and type of infectious complications, as well as the requirement of conditioning prior toHSCT.Although long-termsurvival is possible in the presence ofmixed chimerism, highlevel donor myeloid engraftment should be targeted to avoid posttransplant neutropenia.

Publication metadata

Author(s): Hoenig M, Lagresle-Peyrou C, Pannicke U, Notarangelo LD, Porta F, Gennery AR, Slatter M, Cowan MJ, Stepensky P, Al-Mousa H, Al-Zahrani D, Pai S-Y, Al Herz W, Gaspar HB, Veys P, Oshima K, Imai K, Yabe H, Noroski LM, Wulffraat NM, Sykora K-W, Soler-Palacin P, Muramatsu H, Al Hilali M, Moshous D, Debatin K-M, Schuetz C, Jacobsen E-M, Schulz AS, Schwarz K, Fischer A, Friedrich W, Cavazzana M

Publication type: Article

Publication status: Published

Journal: Blood

Year: 2017

Volume: 129

Issue: 21

Pages: 2928-2938

Print publication date: 25/05/2017

Online publication date: 25/05/2017

Acceptance date: 13/03/2017

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: American Society of Hematology


DOI: 10.1182/blood-2016-11-745638


Altmetrics provided by Altmetric